Your browser doesn't support javascript.
loading
Ocular adnexal sebaceous carcinoma in a patient with Li-Fraumeni syndrome.
Hsu, Chia W; Peterson, Cornelia W; Eberhart, Charles G; Meyer, Christian F; Armstrong, Deborah K; Fiallos, Katie; Campbell, Ashley A.
Afiliación
  • Hsu CW; Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Peterson CW; Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Eberhart CG; Department of Comparative Pathobiology, Tufts University Cummings School of Veterinary Medicine, North Grafton, Massachusetts, USA.
  • Meyer CF; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Armstrong DK; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Fiallos K; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Campbell AA; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Orbit ; : 1-5, 2024 Jul 29.
Article en En | MEDLINE | ID: mdl-39072610
ABSTRACT
Li-Fraumeni syndrome (LFS) is caused by a pathogenic germline variant at the TP53 locus and is associated with an increased predisposition to a variety of cancers. The neoplasms most frequently associated with LFS are sarcomas, breast cancer, brain tumors, and adrenocortical carcinomas. In this case report, we present a 43-year-old male diagnosed with an ocular adnexal sebaceous carcinoma of the right upper eyelid who was confirmed to have LFS with subsequent genetic testing. The mutational profile of both the patient's genetic screen and tumor sequencing were congruent, demonstrating the same pathogenic loss-of-function TP53 variant. This case report highlights the importance of pursuing genetic testing in patients with a history of multiple tumor types, particularly those with uncommon diagnoses. In this case, confirmation of LFS had important implications for personalized patient care, including identification of contraindicated treatment interventions and the imaging modalities necessary for vigilant follow-up screening.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Orbit Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Orbit Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos